癌变·畸变·突变 ›› 2005, Vol. 17 ›› Issue (3): 156-159.doi: 10.3969/j.issn.1004-616x.2005.03.008

• 论著 • 上一篇    下一篇

α-生育酚琥珀酸酯对S180荷瘤小鼠抗肿瘤作用的实验研究

李红卫;苏  怡;王玉燕;吴 坤   

  1. 哈尔滨医科大学公共卫生学院营养与食品卫生教研室, 黑龙江 哈尔滨 150001
  • 收稿日期:2005-01-18 修回日期:2005-03-01 出版日期:2005-05-30 发布日期:2005-05-30
  • 通讯作者: 吴 坤

Experimental Study on the Antineoplastic Effect of α-Tocopheryl Succinate on Murine S180 Sarcoma

LI Hong-wei;SU Yi;WANG Yu-yan;WU Kun   

  1. Department of Nutrition and Food Hygiene, School of Public Health, Harbin Medical University,Harbin 150001,Heilongjiang,China
  • Received:2005-01-18 Revised:2005-03-01 Online:2005-05-30 Published:2005-05-30
  • Contact: WU Kun

摘要: 背景与目的: 探讨α-生育酚琥珀酸酯(α-Tocopheryl succinate, α-TOS)对S180荷瘤小鼠的抗肿瘤作用及对免疫功能的影响。 材料与方法: 建立小鼠克洛氏(S180)肉瘤动物模型,以α-TOS 40 mg/kg和80 mg/kg剂量肌肉注射连续5 d,同时设肿瘤模型对照组、环磷酰胺阳性对照组和阴性对照组,观察肿瘤抑制率和各组实验动物血像变化;以乳酸脱氢酶法检测α-TOS对实验动物NK(Nature killer,NK)细胞杀伤活性的影响;采用流式细胞术检测各实验组动物T淋巴细胞亚群,计算CD4+/CD8+比值。 结果: α-TOS 40 mg/kg和80 mg/kg剂量组对S180荷瘤小鼠肿瘤抑制率分别为32.38 %和38.92 %;血液白细胞含量均明显高于阳性对照组;NK细胞杀伤活性高于肿瘤模型对照组;与肿瘤模型对照组相比较,α-TOS 处理组CD3+百分率显著增高,差异有统计学意义,CD4+/CD8+比值接近于阴性对照组。 结论: α-TOS能抑制S180荷瘤小鼠肿瘤的生长,无降低白细胞的副作用,并能缓解和改善S180荷瘤小鼠免疫力低下和免疫紊乱状态,提示α-TOS可能成为一种有效的肿瘤化学治疗药物。

关键词: α-生育酚琥珀酸酯, S180肉瘤, 抗肿瘤作用

Abstract: BACKGROUND & AIM: To investigate the effects of α-tocopheryl succinate(α-TOS) on S180 sarcoma and immune functions in tumor-bearing mice. MATERIAL AND METHODS: The experimental animals were divided into 5 groups, negative control, tumor model, α-TOS treatment at dose 40 mg/kg and 80 mg/kg, and cyclophosphamide positive group.α-TOS was injected intramuscly into the transplanted S180 sarcoma on mice for 5 days. The inhibitory rates of α-TOS on tumor and subsequent changes in hemogram were observed;nature killer(NK) cell cytotoxicity and the proportion of T lymphocyte subsets were detected by lactate dehydrogenase method and Flow Cytometer, respectively. RESULTS: The inhibitory rate of α-TOS at dose 40 mg/kg and 80 mg/kg on S180 sarcoma were 32.38 % and 38.92 %, respectively; the amounts of leucocytes in α-TOS treatment groups were much higher than positive control (P<0.01); the NK cytotoxicity and the proportions of CD3+ became much higher in α-TOS treatment groups compared with the tumor model(P<0.05 and P<0.01), CD4+/CD8+ ratios were closed to the negative control. CONCLUSION: α-TOS could be a potent cancer chemotherapeutic agent through inhibiting the growth of S180 sarcoma and improving the immunal function in tumor-bearing mice, without interfering the number of leucocytes.

Key words: α-Tocopheryl succinate, S180 sarcoma, antineoplastic effect